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AbsTrACT
Objectives to investigate sex differences in left 
ventricular remodelling and outcome in patients 
undergoing surgical or transcatheter aortic valve 
replacement (saVr/taVr).
Methods in this multicentre, observational, outcome 
study with imaging core-lab analysis, patients with 
severe aortic stenosis (as) listed for intervention at 
one of six UK centres were prospectively recruited and 
underwent cardiovascular magnetic resonance imaging. 
the primary endpoint was all-cause mortality and 
secondary endpoint was cardiovascular mortality.
results 674 patients (425 men, 249 women, age 
75±14 years) were included: 399 saVr, 275 taVr. 
Women were older, had higher surgical risk scores and 
underwent taVr more frequently (53% vs 33.6%, 
p<0.001). More men had bicuspid aortic valves (BaVs) 
(26.7% vs 14.9%, p<0.001) and demonstrated more 
advanced remodelling than women. During a median 
follow-up of 3.6 years, 145 (21.5%) patients died, 
with no significant sex difference in all-cause mortality 
(23.3% vs 20.5%, p=0.114), but higher cardiovascular 
mortality in women (13.7% vs 8.5%, p=0.012). there 
were no significant sex-related differences in outcome 
in the saVr or taVr subgroups, or after excluding those 
with BaV. Factors independently associated with all-
cause mortality were age, left ventricular ejection fraction 
(lVeF), BaV (better) and myocardial fibrosis detected 
with late gadolinium enhancement (lge) in men, 
and age, lVeF and lge in women. age and lge were 
independently associated with cardiovascular mortality in 
both sexes.
Conclusions Men demonstrate more advanced 
remodelling in response to a similar severity of as. the 
higher cardiovascular mortality observed in women 
following aVr is accounted for by women having less 
BaV and higher risk scores resulting in more taVr. lge is 
associated with a worse prognosis in both sexes.
InTrOduCTIOn
Male and female patients remodel differently in 
response to pressure overload/ischaemia induced 
by aortic stenosis (AS). Remodelling is defined 
as a change in shape, structure or function of the 
heart. While echocardiographic studies suggest 
more concentric remodelling in women,1 2 recent 
cardiovascular magnetic resonance (CMR) imaging 
studies have confirmed higher left ventricular 
(LV) volumes, mass index, mass/volume, lower EF 
and more late gadolinium enhancement (LGE), a 
marker of focal fibrosis, in men.3–5 LGE is associ-
ated with adverse prognosis following aortic valve 
replacement (AVR).6–8
Despite more advanced remodelling in men, 
women appear to have worse outcomes following 
surgical AVR (SAVR)9–11 in some studies but not 
others.12 13 Recent studies using transcatheter AVR 
(TAVR) have demonstrated a survival benefit in 
women.14 15 Female sex has been found to be an 
independent predictor of symptom onset in AS16 
and a predictor of cardiovascular mortality in our 
recently published multicentre study.17 The aim of 
this study was to investigate the apparent discrep-
ancy between remodelling and outcome between 
sexes in patients undergoing SAVR/TAVR.
MeThOds
study design
In this multicentre, longitudinal, observational 
outcome study conducted in the UK,17 patients 
with severe AS listed for intervention at one of 
six cardiothoracic surgical units were prospec-
tively recruited. Patients>18 years of age with 
severe AS (one of the following: aortic valve area 
(AVA)<1 cm2, peak pressure gradient >64 mmHg, 
mean pressure gradient (MPG) >40 mmHg) who 
had undergone CMR for research purposes were 
included. The primary endpoint was all-cause 
mortality. The secondary endpoint was cardio-
vascular disease-related mortality, as defined by 
diagnosis on the UK death certificate. Data were 
collected on baseline characteristics (demographics, 
medical and drug history), surgical risk scores (STS 
V.2.73 and EuroSCORE II) and aortic valve gradi-
ents and area from transthoracic echocardiography, 
at the time of CMR.
CMr acquisition
CMR was performed on 1.5/3.0 T scanners using 
standardised protocols including cine imaging for 
ventricular volumes and function, phase-contrast 
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Table 1 Baseline characteristics
Variable Male (n=425) Female (n=249) P value
Age (years) 71.8±10.5 74.9±10.7 <0.001
BMI (kg/m2) 27.8±4.6 27.2±5.8 0.198
SBP (mmHg) 133.9±19.4 136.9±22.1 0.107
Hypertension (n (%)) 228 (53.6) 130 (52.2) 0.718
AF (n (%)) 47 (11.1) 37 (14.9) 0.149
Diabetes (n (%)) 98 (23.1) 48 (19.3) 0.250
Known CAD (n(%)) 140 (32.9) 46 (18.5) <0.001
Previous PCI (n(%)) 31 (7.7) 26 (10.6) 0.203
Previous CABG (n(%)) 46 (11.4) 12 (4.9) 0.005
ACEI/ARB (n (%)) 177 (43.5) 85 (36.8) 0.099
Beta-blocker (n (%)) 148 (35.0) 92 (36.9) 0.609
Statin (n (%)) 266 (63.8) 140 (57.1) 0.090
BAV (n(%)) 112 (26.5) 37 (14.9) <0.001
STS mortality score (%) 1.56 [0.98, 2.55) 2.30 [1.32, 4.16) <0.001
EuroSCORE II (%) 1.45 [0.91, 3.12) 2.12 [1.32, 4.16) <0.001
NYHA class
I 60 (15.6) 21 (9.3) 0.020
II 170 (44.3) 88 (39.1)
III 143 (37.2) 105 (46.7)
IV 11 (2.9) 11 (4.9)
Echocardiographic data
MPG (mmHg) 48.1±16.4 49.2±14.6 0.451
PPG (mmHg) 80.9±24.9 83.9±23.1 0.157
AVA (cm2) 0.76±0.23 0.66±0.23 <0.001
AVAI (cm2/m2) 0.38±0.11 0.38±0.13 0.753
Baseline cardiovascular magnetic resonance data
LVEDVI (mL/m2) 87.2±26.5 79.2±22.1 <0.001
LVESVI (mL/m2) 39.2±24.6 33.7±20.1 0.002
LVSVI (mL/m2) 48.0±12.1 45.5±10.2 0.006
LVEF (%) 60.0 [51.0, 67.0) 62.0 [53.0, 69.0) 0.024
LVMI (g/m2) 88.6±24.5 74.5±21.6 <0.001
LV mass/volume 1.06±0.29 0.97±0.25 <0.001
RVEDVI (mL/m2) 72.1±16.8 66.1±16.6 <0.001
RVEF (%) 64.0 [57.0, 70.0) 65.0 [59.0, 73.0) 0.025
LAVI (mL/m2) 55.6±21.1 58.3±21.9 0.127
LGE present (n(%)) 248 (62.6) 93 (42.9) <0.001
  Non-infarct pattern (n(%)) 157 (39.6) 65 (30.0) 0.017
  Infarct pattern (n(%)) 91 (23.0) 28 (12.9) 0.003
LGE mass (g) 1.90 [0.00, 6.51) 0.00 [0.00, 2.40) <0.001
LGE (%LV mass) 1.12 [0.00, 3.60) 0.00 [0.00, 1.63) <0.001
Intervention type
SAVR (n(%)) 282 (66.4) 117 (47.0) <0.001
TAVR (n(%)) 143 (33.6) 132 (53.0) <0.001
P values using independent t-test/Mann-Whitney U test/Χ2 test as appropriate. p<0.05 shown in Bold.
ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor 
blocker; AVA, aorticvalve area; AVAI, aortic valve area index (to BSA); BAV, bicuspidaortic valves; BMI, 
body mass index; BSA, body surface area; CABG, coronary artery bypass graft; CAD, coronary artery 
disease; LAVI, left atrial volume index; LGE, late gadolinium enhancement; LV, left ventricle; LVEDVI, 
LV end-diastolic volume index; LVEF, LV ejection fraction; LVESVI, LV end-systolic volume index; LVMI, 
LV mass index; LVSVI, LV stroke volume index; MPG, mean pressure gradient; NYHA, New York Heart 
Association; PCI, percutaneous coronary intervention; PPG, peak pressure gradient; RVEDVI, right 
ventricular (RV) end-diastolic volume index; RVEF, RV ejection fraction; SAVR, surgical aortic valve 
replacement; SBP, systolic blood pressure; STS, society of thoracic surgeons; TAVR, transcatheter aortic 
valve replacement.
Figure 1 An example of a male (top row) and female (bottom row) 
patient with similar degree of aortic stenosis, showing cine stills (a-c, e, 
f), LGE imaging (d, h) and Continuous Wave Doppler through the aortic 
valve on echocardiography (g). AVAI, aortic valve area index (to BSA); 
LGE, late-gadolinium enhancement; LVEDVI, left ventricle end-diastolic 
volume index; LVMI, left ventricle mass index; MPG, mean pressure 
gradient; PPG, peak pressure gradient.
Table 2 Outcomes for all patients, SAVR group and TAVR group
Outcome Male (n=425) Female (n=249) P value*
All patients: n (%)
  All-cause mortality 87 (20.5) 58 (23.3) 0.114
  Cardiovascular mortality 36 (8.5) 34 (13.7) 0.012
SAVR group only: n (%)
  All-cause mortality 37 (13.1) 15 (12.8) 0.966
  Cardiovascular mortality 11 (3.9) 8 (6.8) 0.206
TAVR group only: n (%)
  All-cause mortality 50 (35) 43 (32.6) 0.752
  Cardiovascular mortality 25 (17.5) 26 (19.7) 0.418
*Log-rank test used.
SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve 
replacement.
velocity-encoded imaging for valve haemodynamics and LGE 
imaging for myocardial scar assessment.7 18 All participating 
centres have previously published single-centre studies in AS, 
with image quality and CMR pulse sequence parameters.16 18–21
Image analysis and data management
The details of data management and image analysis have been 
published.17 Anonymised data were collected and managed using 
Research Electronic Data Capture (REDCap) software.22 All 
deaths were identified through the UK National Health Service 
National Spine Database. Cardiovascular mortality was estab-
lished in all deceased from the death certificates and adjudicated 
by two blinded readers (PB and JPG). All CMR scans were re-an-
alysed in core-lab fashion,17 with each centre reporting a single 
component for all patients, after training and reproducibility 
assessment, and using standardised operating procedures, on 
CVI42 software (Circle Calgary, Canada). The full-width-half-
maximum technique was used to quantify LGE.
statistical analysis
Normality was assessed using the Shapiro-Wilk test, histograms 
and Q-Q plots using SPSS V.24.0 software (Statistical Package 
for the Social Sciences, Chicago, Illinois, USA). For continuous 
data, mean±SD for normally distributed data and median(IQR) 
for non-parametric data are presented. Categorical variables are 
expressed as counts and percentage. Data between the sexes were 
compared using independent t-test or Mann-Whitney U test. 
The Χ2 test was used for categorical variables. P values <0.05 
were considered statistically significant. Univariate associates 
of outcomes were determined using Cox proportional hazards 
models, with the inclusion of sex-interaction variable into the 
model. Variables for the multivariable models were selected based 
on statistical significance (p<0.10) and clinical relevance, while 
avoiding co-linear variables (LV volumes were not included in 
addition to left ventricular ejection fraction (LVEF), as they are 
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Figure 2 Kaplan-Meier survival curves for male and female patients: 
(a) all-cause mortality and (b) cardiovascular mortality.
Figure 3 Kaplan-Meier survival curves for SAVR subgroup (top panel), 
TAVR subgroup (middle panel) and trileaflet aortic valve patients 
only (bottom panel), showing all-cause mortality (left panel) and 
cardiovascular mortality (right panel). All p>0.05 on Log-rank test. 
SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve 
replacement.
used in its calculation). As Society of Thoracic Surgeons (STS) 
score incorporates most clinical and demographic variables, this 
was not included in the initial model, but the added effect of 
LGE was tested in separate models. Survival was evaluated using 
the Kaplan-Meier method and compared between sexes using 
the log-rank test. The index date was the date of CMR. HRs 
were expressed as mean±95% CI.
resulTs
baseline characteristic
From 703 patients who underwent CMR, 29 were managed 
medically, and were excluded from further analysis (15 men and 
14 women). This left 674 patients, 425 men and 249 women: 
mean age 75±14 years, AVA index 0.38±0.14 cm2/m2, MPG 
of 46±18 mmHg. Female patients were older, with higher STS 
and EuroSCORES (table 1). The prevalence of coronary artery 
disease and bicuspid aortic valve (BAV) was higher in men. AS 
severity was similar (no statistically significant difference in 
trans-thoracic echocardiogram (TTE)-measured pressure gradi-
ents and corrected AVA). Men demonstrated higher body surface 
area-corrected ventricular volumes, LV mass and mass/volume; 
marginally lower EF and a greater prevalence and amount of 
LGE (figure 1). A greater proportion of women underwent TAVR 
(53% vs 33.6%, p<0.001). There was no statistically significant 
difference in age or AS severity of the men and women in either 
SAVR-only or TAVR-only subgroup.
Outcome
During a median follow-up of 3.6 years (IQR 2.6–5.9 years, 
range 9.9 years), 145 (21.5%) patients died: 87 (20.5%) men and 
58 (23.3%) women (table 2). There was no significant difference 
in all-cause mortality, but a higher incidence of cardiovascular 
mortality in women (13.7% vs 8.5%, p=0.012 on log-rank test) 
(figure 2). There were no significant sex differences in all-cause 
or cardiovascular mortality in the TAVR-only or SAVR-only 
subgroup (figure 3, table 2).
Factors associated with outcome
As we have previously shown sex to be independently associated 
with cardiovascular mortality in the overall cohort,17 univariate 
associations were assessed with the inclusion of the variable’s 
interaction with sex in the regression model. Common associ-
ates of all-cause mortality (table 3) included age, atrial fibrilla-
tion, coronary disease, surgical risk scores, left atrial volume, LV 
end-systolic and stroke volumes, left and right ventricular EF 
(L/RVEF) and the presence/amount of LGE. In addition, BAV 
morphology and non-infarct pattern LGE were significant in 
men, while previous coronary intervention and infarct-pattern 
LGE were significant in women. AS severity was not associated 
in either sex.
The following variables were entered into a multivariate regres-
sion model in a single step: age, AF, BAV, CAD, LVEF, RVEF, LGE 
presence, LAVI and LVMI, as well as the sex-interaction variable 
with BAV and LVMI. The independently associated variables were 
age, LVEF and LGE in both sexes, with the addition of BAV in men 
(table 4). The same variables remained independent on entering 
all variables of interest and their sex-interaction variables into a 
backward selection model.
Univariate associations with cardiovascular mortality (table 5)
were similar, with the addition of diabetes for both sexes, lack of 
association of coronary disease and non-infarct pattern LGE in 
men, and fewer remodelling parameters in women. Independent 
associations with cardiovascular mortality included age and LGE 
in both sexes, when all variables shown in table 4 were entered 
into the model in a single step, with the addition of AF in men, 
and AF and diabetes in women on using a backward selection 
model.
We also performed multivariable analysis with stepwise 
selection of LGE in addition to STS score, and both remained 
independently associated with all-cause and cardiovascular 
mortality in both sexes, with LGE providing incremental prog-
nostic information.
exclusion of bAV patients
We excluded BAV to remove the bias of the younger BAV subgroup 
in men (mean age 63.3±11.4 vs 75.6±8.8 years, p<0.01 and 
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Table 3 Univariate associations with all-cause mortality
Male Female Interaction p value
Parameter hr 95% CI P value hr 95% CI P value
  Age 1.08 1.05 to 1.10 <0.001 1.07 1.04 to 1.10 <0.001 0.846
  BMI 0.99 0.95 to 1.04 0.658 0.97 0.92 to 1.02 0.180 0.497
  Hypertension 1.02 0.67 to 1.55 0.935 1.12 0.67 to 1.89 0.662 0.773
  Diabetes 1.38 0.88 to 2.18 0.165 1.33 0.71 to 2.47 0.371 0.919
  Atrial fibrillation 2.61 1.57 to 4.35 <0.001 1.91 1.03 to 3.54 0.041 0.442
  BAV 0.22 0.11 to 0.45 <0.001 0.57 0.25 to 1.34 0.199 0.091
  Previous MI 1.56 0.88 to 2.76 0.130 1.03 0.32 to 3.32 0.956 0.536
  Previous PCI/CABG 1.13 0.67 to 1.90 0.654 2.83 1.57 to 5.11 0.001 0.022
  Known CAD 1.58 1.03 to 2.42 0.037 2.61 1.48 to 4.62 0.001 0.165
  ACE-I/ ARB 1.55 1.00 to 2.40 0.052 1.14 0.64 to 2.04 0.663 0.413
  BB 1.08 0.70 to 1.67 0.717 1.40 0.82 to 2.37 0.215 0.467
  Statin 1.10 0.70 to 1.73 0.692 1.30 0.75 to 2.27 0.352 0.638
  STS score 1.21 1.13 to 1.29 <0.001 1.16 1.09 to 1.23 <0.001 0.343
  EuroSCORE 1.08 1.03 to 1.13 0.002 1.12 1.07 to 1.18 <0.001 0.252
Echo data
  PPG 1.00 0.99 to 1.01 0.919 1.01 1.00 to 1.02 0.171 0.262
  MPG 1.00 0.99 to 1.02 0.821 1.01 0.99 to 1.03 0.289 0.486
  AVAI 0.25 0.02 to 2.62 0.247 0.37 0.03 to 4.70 0.443 0.824
CMR data
  LVEDVI 1.00 0.99 to 1.01 0.621 1.01 1.00 to 1.02 0.049 0.196
  LVESVI 1.01 1.00 to 1.02 0.028 1.02 1.01 to 1.03 <0.001 0.066
  LVSVI 0.97 0.95 to 0.99 <0.001 0.97 0.95 to 1.00 0.026 0.828
  LVEF 0.98 0.97 to 0.99 0.001 0.97 0.95 to 0.98 <0.001 0.225
  RVEDVI 1.00 0.98 to 1.01 0.487 1.00 0.99 to 1.02 0.696 0.450
  RVEF 0.98 0.96 to 1.00 0.012 0.98 0.95 to 1.00 0.027 0.895
  LAVI 1.01 1.00 to 1.02 0.050 1.01 1.00 to 1.03 0.011 0.548
  LVMI 0.99 0.99 to 1.00 0.220 1.01 1.00 to 1.02 0.054 0.024
  LV mass/volume 0.51 0.24 to 1.09 0.081 1.57 0.56 to 4.40 0.388 0.084
  LGE presence 2.90 1.62 to 5.17 <0.001 2.05 1.16 to 3.62 0.014 0.402
   LGE non-infarct 1.64 1.05 to 2.57 0.030 1.30 0.72 to 2.35 0.388 0.534
   LGE infarct 1.57 0.97 to 2.54 0.067 2.69 1.34 to 5.43 0.006 0.213
  LGE (g) 1.02 1.00 to 1.05 0.022 1.09 1.04 to 1.14 0.001 0.026
  LGE (%) 1.06 1.02 to 1.11 0.005 1.12 1.06 to 1.19 <0.001 0.157
Abbreviations are as per table 1. Hazard ratios are per unit of the variable. Interaction p value is for interaction of variable with sex, which was included in the model.
lower incidence of diabetes, AF and coronary disease). This left 
313 male and 212 female patients, with similar sex differences in 
remodelling parameters (higher mass, volumes and mass/volume in 
men), but differences in LVEF, RVEF and LV stroke volume index 
no longer being significant (online supplementary table 1). There 
was no significant sex difference in all-cause or cardiovascular 
mortality (table 2, figure 2, online supplementary table 2). Univar-
iate associations, corrected for sex-interactions, are presented in 
online supplementary tables 3,4. On multivariable analysis entering 
all variables in a single step, independent associations of all-cause 
mortality were age and LGE in both sexes, with the addition of AF 
in women when using a backward selection model. Independent 
associations of cardiovascular mortality were age, AF and LGE 
in men, with the addition of diabetes in women. The same vari-
ables remained significant on backward stepwise selection (online 
supplementary table 5).
dIsCussIOn
This large multicentre CMR study confirms sex differences in 
LV remodelling. Although there was no significant difference 
in all-cause mortality, cardiovascular mortality was higher in 
women. However, these observed differences are accounted 
for by men being younger with more BAV, while women having 
more TAVR likely due to higher risk profile, possibly reflecting 
differences in the referral practices for male and female patients. 
LGE was independently associated with all-cause and cardiovas-
cular mortality in both sexes.
sex differences in lV remodelling
We have confirmed findings from previous single-centre studies 
utilising CMR3–5 that for a similar severity of AS, men demon-
strate more advanced LV remodelling, with larger indexed 
volumes, mass, mass/volume and lower EF, in addition to more 
focal fibrosis (LGE). While women were thought to demonstrate 
more concentric remodelling based on older TTE measurements 
of higher relative wall thickness,23 24 this was traditionally based 
on a single basal slice, often using M-mode, which has many 
assumptions about the shape and symmetry of the LV. CMR 
overcomes many of these limitations and is now regarded as the 
gold standard for quantitative LV assessment, and the finding of 
greater concentric remodelling (ie, higher mass/volume) in men 
has now been confirmed in other CMR studies.4 Despite this 
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Table 4 Univariate associations with cardiovascular mortality
Male (n=425) Female (n=249)
Interaction p 
value
Parameter hr 95% CI P value hr 95% CI P value
  Age 1.09 1.05 to 1.14 <0.001 1.06 1.02 to 1.10 0.003 0.336
  BMI 1.02 0.95 to 1.10 0.521 0.94 0.88 to 1.01 0.079 0.094
  Hypertension 1.08 0.56 to 2.08 0.824 0.98 0.50 to 1.92 0.943 0.837
  Diabetes 1.99 1.02 to 3.89 0.044 2.13 1.04 to 4.38 0.039 0.891
  AF 4.05 1.99 to 8.23 <0.001 2.29 1.07 to 4.91 0.033 0.283
  BAV 0.07 0.01 to 0.48 0.007 0.85   0.33 to 2.21 0.745 0.023
  Previous MI 1.58 0.66 to 3.80 0.309 1.64 0.50 to 5.38 0.418 0.962
  Previous PCI/CABG 1.03 0.45 to 2.36 0.945 3.56 1.73 to 7.32 0.001 0.027
  Known CAD 1.76 0.91 to 3.40 0.092 3.15 1.55 to 6.40 0.001 0.237
  ACE-I/ ARB 2.43 1.19 to 4.94 0.014 0.93 0.44 to 1.94 0.838 0.065
  BB 1.61 0.84 to 3.11 0.152 1.31 0.66 to 2.60 0.440 0.666
  Statin 1.66 0.78 to 3.53 0.190 1.07 0.53 to 2.16 0.844 0.407
  STS score 1.27 1.17 to 1.39 <0.001 1.15 1.06 to 1.24 <0.001 0.080
  EuroSCORE 1.11 1.04 to 1.18 0.003 1.13 1.07 to 1.20 <0.001 0.627
Echo data
  PPG 0.99 0.98 to 1.01 0.451 1.00 0.98 to 1.02 0.865 0.661
  MPG 0.99 0.96 to 1.02 0.425 1.00 0.97 to 1.02 0.705 0.764
  AVAI 0.04 0.00 to 1.73 0.092 1.34 0.06 to 27.67 0.851 0.148
CMR data
  LVEDVI 1.01 0.99 to 1.02 0.442 1.01 1.00 to 1.03 0.169 0.586
  LVESVI 1.01 1.00 to 1.02 0.014 1.02 1.01 to 1.04 0.006 0.414
  LVSVI 0.95 0.92 to 0.98 <0.001 0.97 0.93 to 1.00 0.050 0.423
  LVEF 0.97 0.95 to 0.98 <0.001 0.96 0.94 to 0.98 <0.001 0.665
  RVEDVI 1.01 0.99 to 1.03 0.443 1.00 0.98 to 1.02 0.751 0.446
  RVEF 0.96 0.93 to 0.98 0.001 0.98 0.95 to 1.00 0.076 0.358
  LAVI 1.02 1.01 to 1.03 0.005 1.02 1.00 to 1.03 0.030 0.673
  LVMI 1.00 0.99 to 1.02 0.932 1.01 0.99 to 1.02 0.409 0.599
  LV mass/volume 0.64 0.21 to 2.00 0.444 0.77 0.19 to 3.12 0.712 0.844
  LGE presence 9.85 2.36 to 41.15 0.002 2.81 1.34 to 5.87 0.006 0.126
  LGE non-infarct 1.67 0.85 to 3.31 0.139 1.29 0.62 to 2.70 0.494 0.614
  LGE infarct 2.56 1.29 to 5.11 0.008 3.94 1.81 to 8.62 0.001 0.418
  LGE (g) (FWHM) 1.03 1.00 to 1.06 0.032 1.10 1.04 to 1.17 0.001 0.029
  LGE (%) (FWHM) 1.07 1.01 to 1.14 0.019 1.15 1.07 to 1.22 <0.001 0.151
Abbreviations are as per table 1.Hazard ratios are per unit of the variable. Interaction p value is for interaction of variable with sex, which was included in the model.
SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.
seemingly more maladaptive response in men, female sex has 
been associated with both earlier symptom onset16 and worse 
mortality in AS.9–11 Putative mechanisms for these differences 
include higher wall stress in women due to less adaptive concen-
tric remodelling for a similar degree of pressure overload, which 
may contribute to earlier symptoms. In fact, in this study, a 
greater proportion of women had New York Heart Association 
(NYHA) III–IV symptoms than men.
referral patterns for intervention
There were more men in the SAVR group (71%), a difference 
that persisted even after removing those with BAVs (69%), with 
the proportions being almost equal for TAVR. This discrep-
ancy in referral for surgical intervention has been noted in both 
historical single-centre studies (68% in a retrospective analysis of 
consecutive procedures10) and a multicentre analysis of an Amer-
ican national database (63%).25 This is also confirmed by the 
UK national cardiac surgery database reporting 60% of patients 
undergoing AVR being men, rising to around 70% for AVR and 
coronary artery bypass graft.26 On the contrary, the proportions 
are almost equal for TAVR in both single-centre studies14 and 
larger registries.27 Both a disparity in referral for testing and 
referral for surgery have been suggested,25 28 possibly due to 
greater incidence of comorbidities or risk scores at presentation 
in female participants.10 11 27 Other data suggest a greater benefit 
of TAVR in high-risk female patients,15 27 possibly leading to more 
women being referred for TAVR. There is also the possibility 
of perceived and/or real higher incidence of patient-prosthesis 
mismatch in women leading to a bias towards TAVR referral, 
and higher cardiovascular mortality. The female patients in our 
study were indeed older, more symptomatic (greater proportion 
of NYHA III–IV symptoms) and had higher surgical risk scores 
at the time of intervention.
Factors associated with outcome
Age and LGE were the common factors associated inde-
pendently with all-cause and cardiovascular mortality in both 
sexes, with LVEF also significant for all-cause mortality. LGE 
also provided incremental prognostic information to STS score, 
which incorporates many clinical variables. The fact LVEF was 
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Table 5 Table 5Multivariable associations with all-cause mortality and cardiovascular mortality
All-cause mortality Cardiovascular mortality
Parameter hr 95% CI P value Interaction p value Parameter hr 95% CI P value
Interaction 
p value
Age 1.06 1.04 to 1.09 <0.001   Age 1.07 1.03 to 1.11 <0.001   
AF 1.57 0.93 to 2.67 0.095   AF 1.89 0.96 to 3.70 0.065   
BAV (M)
(F)
0.33 0.13 to 0.84 0.020   0.036 BAV (M)
(F)
0.15 0.02 to 1.09 0.061   0.025
1.35 0.50 to 3.67 0.554 2.32 0.82 to 6.61 0.114
CAD 1.25 0.83 to 1.87 0.290   CAD 1.59 0.90 to 2.82 0.110   
LVEF 0.99 0.97 to 1.00 0.044   LVEF 0.99 0.97 to 1.00 0.077   
RVEF 1.00 0.98 to 1.02 0.812   LAVI 1.00 0.99 to 1.01 0.810   
LGE 2.27 1.47 to 3.51 <0.001   LGE 3.17 1.65 to 6.09 0.001   
LAVI 1.00 0.99 to 1.01 0.316   Diabetes 1.66 0.93 to 2.97 0.086   
LVMI (M)
(F)
0.99 0.98 to 1.00 0.191   0.030   
1.01 1.00 to 1.03 0.108
Multivariate analysis performed with all independent variables entered into the model in one step. Interaction p value is shown for those variables which had interaction with 
sex on univariate analysis, and had their sex-interaction variable included in the multivariate model, for which separate HR(CI) are shown for men and women. The HR (CI) are 
the same for both sexes for the other variables. Abbreviations are as per table 1. ‘LGE’ implies ‘LGE presence’ as a categorical variable. On testing just STS score and LGE, both 
remain independent on forward stepwise selection.
Key questions
What is already known on this subject?
 ► Sex differences in remodelling and post-aortic valve 
replacement (AVR) outcome have been reported in aortic 
stenosis (AS), with men demonstrating more advanced 
remodelling and worse outcomes in women in some studies.
What might this study add?
 ► In this large multicentre, prospective longitudinal outcome 
study of patients undergoing cardiovascular magnetic 
resonance imaging before surgical/transcatheter AVR 
(SAVR/TAVR), during a median follow-up of 3.6 years 
(IQR 2.6–5.9 years), there was no significant difference 
in all-cause mortality (23.3% vs 20.5%, p=0.114), but 
higher cardiovascular mortality in women (13.7% vs 
8.5%, p=0.012). However, this finding did not persist 
after accounting for type of intervention and prevalence 
of bicuspid aortic valve. A greater proportion of women 
underwent TAVR (53% vs 33.6%, p<0.001), with higher 
risk scores. Late gadolinium enhancement presence was 
associated with adverse prognosis in both sexes, even after 
AVR.
how might this impact on clinical practice?
 ► Clinicians need to be aware of a possible bias in not referring 
female patients with severe AS for intervention and that 
when other risk factors are accounted for, cardiovascular and 
all-cause mortality are similar in men and women. Further 
studies are needed to define the best stratification tools in 
AS, with possible sex-specific cut-offs to define severity and 
timing of intervention.
not associated with cardiovascular outcomes may relate to the 
fact that few patients had impaired LV function. As expected, 
there was a greater proportion of BAVs in the male subgroup. 
BAV is thought to represent a different pathology to degener-
ative trileaflet AS, with better survival post AVR in a large age 
and sex matched cohort.29 Despite its exclusion, age and LGE 
remained significant for all-cause mortality, where as LGE was 
significant for cardiovascular mortality in only men, with the 
addition of diabetes in women and AF in both sexes, as the 
younger and fitter BAV patients were excluded.
Is earlier intervention warranted?
Given that women in our multicentre study were older, more 
symptomatic, with higher risk scores, and more frequently 
referred for TAVR, differences in care pathways for male 
and female patients may exist. It is possible that due to more 
advanced remodelling, men tend to get referred earlier for 
a similar degree of AS. In addition, subjective differences in 
interpretation and acknowledgement of symptoms may add to 
this potential referral bias. The association of LGE with poor 
outcome even after intervention in both sexes, supports the 
need for earlier intervention in AS, before fibrosis develops, and 
the need for trials to establish the best stratification tools. The 
EVOLVED (Early Valve Replacement guided by Biomarkers of 
Left Ventricular Decompensation in Asymptomatic Patients with 
Severe AS) trial is underway, which specifically addresses this 
question (NCT03094143).
There are limitations to our study.17 This was an observa-
tional study of patients at surgical centres with an interest in 
CMR, potentially introducing selection bias. Certain patient 
groups with a contraindication to CMR were excluded 
(advanced renal failure and non-compatible devices). LGE 
was not performed in a small minority of patients (n=61), 
and T1 mapping and biomarker analysis are also lacking. We 
did not objectively measure frailty or exercise capacity. The 
prevalence of occult amyloidosis, which has been shown to be 
present in 4%–8% of severe AS patients,30 is also unknown, 
as biopsy or radiolabelled scans were not performed as part 
of this study.
COnClusIOn
Men demonstrate more advanced remodelling in response to 
a similar degree of AS. The higher cardiovascular mortality 
observed in women following AVR is accounted for by women 
having less BAV and higher risk scores resulting in more TAVR. 
LGE is associated with a worse prognosis in both sexes.
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